CAM
TEVA icon

Cresset Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cresset Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
9,930
+2,976
+43% +$99.1K ﹤0.01% 1329
2026
Q1 		$209K Buy
+6,954
New +$224K ﹤0.01% 1449
2025
Q1 		– Sell
-27,351
Closed -$603K – 1851
2024
Q4 		$603K Sell
27,351
-3,261
-11% -$59.3K ﹤0.01% 998
2024
Q3 		$552K Buy
30,612
+2,849
+10% +$49.9K ﹤0.01% 1465
2024
Q2 		$451K Buy
27,763
+6,804
+32% +$105K ﹤0.01% 1493
2024
Q1 		$296K Buy
20,959
+2,970
+17% +$37.4K ﹤0.01% 1592
2023
Q4 		$188K Sell
17,989
-416
-2% -$3.88K ﹤0.01% 1705
2023
Q3 		$188K Buy
18,405
+6,294
+52% +$58.6K ﹤0.01% 1643
2023
Q2 		$91.2K Buy
+12,111
New +$98.2K ﹤0.01% 1817
2023
Q1 		– Sell
-20,691
Closed -$189K – 864
2022
Q4 		$189K Buy
20,691
+392
+2% +$3.42K ﹤0.01% 644
2022
Q3 		$164K Buy
20,299
+70
+0.3% +$619 ﹤0.01% 811
2022
Q2 		$150K Sell
20,229
-1,304
-6% -$11.4K ﹤0.01% 860
2022
Q1 		$202K Sell
21,533
-3,233
-13% -$27K ﹤0.01% 912
2021
Q4 		$198K Buy
24,766
+958
+4% +$8.65K ﹤0.01% 1052
2021
Q3 		$232K Buy
23,808
+1,602
+7% +$15K ﹤0.01% 964
2021
Q2 		$220K Sell
22,206
-258
-1% -$2.73K ﹤0.01% 909
2021
Q1 		$260K Buy
22,464
+1,850
+9% +$21.2K ﹤0.01% 743
2020
Q4 		$199K Buy
20,614
+583
+3% +$5.58K ﹤0.01% 731
2020
Q3 		$181K Hold
20,031
– – ﹤0.01% 659
2020
Q2 		$247K Buy
20,031
+1,449
+8% +$16.4K 0.01% 535
2020
Q1 		$167K Buy
18,582
+219
+1% +$2.24K 0.01% 526
2019
Q4 		$180K Sell
18,363
-501
-3% -$4.47K ﹤0.01% 571
2019
Q3 		$130K Buy
18,864
+63
+0.3% +$483 ﹤0.01% 516
2019
Q2 		$174K Sell
18,801
-524
-3% -$6.32K 0.01% 455
2019
Q1 		$303K Buy
19,325
+18,813
+3,674% +$332K 0.01% 271
2018
Q4 		$8K Buy
+512
New +$10.5K ﹤0.01% 915

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Cresset Asset Management's TEVA Position: Q2 2026 in Review

Cresset Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 43% in Q2 2026, buying an estimated $99.1K and bringing the position to 9,930 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

Cresset Asset Management first reported a position in TEVA in Q4 2018 and has held it in 26 quarters since. The position peaked at $603K in Q4 2024. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Cresset Asset Management held 9,930 shares of Teva Pharmaceuticals worth $336K as of Q2 2026.
  • Cresset Asset Management bought 2,976 Teva Pharmaceuticals shares in Q2 2026, an estimated $99.1K.
  • Teva Pharmaceuticals made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1329 holding.
  • Cresset Asset Management first reported a position in Teva Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Cresset Asset Management's Teva Pharmaceuticals position peaked at $603K in Q4 2024.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.